TaiMed Biologics
4147 · TPEx
Public Market Listing
4147TPEx
Live quotes, historical charts, and market capitalization for TaiMed Biologics are available on Yahoo Finance.
View quote & market cap on Yahoo Finance ↗External market data link · No third-party exchange redistribution
Assets
(2 total)
2Total Assets
1Approved
0Phase 3 / Filed
1Phase 1–2 / Early
1Diseases
| Target & Modality | |||
|---|---|---|---|
Ibalizumab(Trogarzo) | Approved | CD4 receptorMonoclonal antibody | HIV |
| Phase 2 | CD4; HIV envelopeCombination | HIV |
Upcoming events
(1 total)
Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
2027 (1)
May 2027 (1)
Est. primary completion 2027-05 · NCT07215468 · CT.gov ↗